Lupin unveils Posaconazole Delayed-Release Tablets
Mumbai, Baltimore: Global pharma major, Lupin Limited, has recently announced the launch of Posaconazole Delayed-Release Tablets, 100 mg, after its alliance partner AET Pharma US Inc. (part of Tiefenbacher Group) received an approval for its abbreviated new drug application (ANDA) from the United States Food and Drug Administration (USFDA).
Posaconazole Delayed-Release Tablets, 100 mg, are the generic equivalent of Noxafil DelayedRelease Tablets, 100 mg, of Merck Sharp & Dohme Corp.
The product is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.
Posaconazole Delayed-Release Tablets, 100 mg (RLD: Noxafil) had estimated annual sales of USD 186 million in the U.S. (IQVIA MAT December 2020).
Read also: Lupin gets USFDA nod for generic equivalent of Kerydin Topical Solution
Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.
